BVF INC IL
Q3 2026 Form 13-F
SAN FRANCISCO, CALIFORNIA
CIK 0001056807
· Institutional investment manager
Consolidated report · includes
1 manager
since Q2 2013
$3.0B Reported Value Total
Reported value
$3.0B
Quarter over quarter
—
Holdings
—
Top-10 concentration
—
Filing Structure
Reports holdings for
- BVF PARTNERS L P IL · File #028-06770 · since Q2 2013
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Mark N. Lampert
President
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 16, 2026 |
| Form | 13F-HR |
| Reported value | $3.0B |
| Positions | 47 |
| Change in reported value | -22.3% |
| New positions | 4 |
| Exited positions | 1 |
| Position turnover | 10.4% |
| Top-10 concentration | 66.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
47 | $3.0B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
44 | $3.9B |
|
Q1 2026 13F
Filed May 15, 2026
|
41 | $3.1B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
41 | $3.0B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
46 | $2.5B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
44 | $2.8B |
|
Q1 2025 13F
Filed May 15, 2025
|
51 | $2.5B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
53 | $3.0B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
55 | $3.4B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
60 | $3.6B |
|
Q1 2024 13F
Filed May 15, 2024
|
62 | $3.6B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
70 | $4.0B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
69 | $3.7B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
67 | $3.6B |
|
Q1 2023 13F
Filed May 15, 2023
|
72 | $2.7B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
78 | $2.4B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
80 | $2.4B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
79 | $2.1B |
|
Q1 2022 13F
Filed May 16, 2022
|
81 | $2.5B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
83 | $2.8B |
34 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | RVMD REVOLUTION MEDICINES INC | $505.1M | 16.61% |
| 2 | KYMR KYMERA THERAPEUTICS INC | $432.9M | 14.24% |
| 3 | GHRS GH RESEARCH PLC | $203.1M | 6.68% |
| 4 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | $187.2M | 6.16% |
| 5 | XNCR XENCOR INC | $155.4M | 5.11% |
| 6 | NKTR NEKTAR THERAPEUTICS | $129.2M | 4.25% |
| 7 | ALKS ALKERMES PLC | $115.4M | 3.79% |
| 8 | STOK STOKE THERAPEUTICS INC | $93.8M | 3.09% |
| 9 | TYRA TYRA BIOSCIENCES INC | $92.2M | 3.03% |
| 10 | ZYME ZYMEWORKS INC | $91.8M | 3.02% |
| 11 | CGEM CULLINAN THERAPEUTICS INC | $88.3M | 2.9% |
| 12 | GPCR STRUCTURE THERAPEUTICS INC | $84.2M | 2.77% |
| 13 | PVLA PALVELLA THERAPEUTICS INC NE | $83.7M | 2.75% |
| 14 | KURA KURA ONCOLOGY INC | $71.7M | 2.36% |
| 15 | ACIU AC IMMUNE SA | $51.9M | 1.71% |
| 16 | GLUE MONTE ROSA THERAPEUTICS INC | $51.0M | 1.68% |
| 17 | ENTX ENTERA BIO LTD | $49.6M | 1.63% |
| 18 | OLMA OLEMA PHARMACEUTICALS INC | $45.8M | 1.51% |
| 19 | CBIO CRESCENT BIOPHARMA INC. | $45.1M | 1.48% |
| 20 | FDMT 4D MOLECULAR THERAPEUTICS IN | $41.2M | 1.36% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.